The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
An open-label phase I dose-finding study of APR-246 in hematological malignancies
TP53 mutations are common in relapsed/refractory (R/R) disease and confer a dismal prognosis in hematological malignancies. APR-246 is the first compound targeting mutant p53 to be used in a clinical trial. Eight patients with R/R non-M3 Acute Myeloid Leukemia (AML) were included in the trial. S. Deneberg, et al., published their results in Blood Cancer Journal in July 2016. The trial was conducted in accordance to the Declaration of Helsinki and ICH-GCP guidelines and was registered at ClinicalTrials.gov (NCT00900614).
The key findings were:
- One AML patient (67.5mg/kg dose) showed a >25% reduction of blast cell count in their peripheral blood. However, the patient was not given any additional treatment due to experiencing serious adverse events (judged as unrelated to the study treatment) at the end of the follow-up period.
- A previously stem cell-transplanted patient with AML (03-101) in third relapse was treated with 135mg/kg APR-246 and went into complete remission. A month prior to inclusion, the patient had 83% blasts in their peripheral blood (judged as overt relapse and no bone marrow was taken) compared with 4% after 4 days of APR-246 treatment and 0% at day 21 bone marrow examination.
These data provide a basis for the further exploration of the use of APR-246 in hematological indications, preferentially in combination with standard chemotherapy.
References
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?